Results from 22 years of Followup in the Göteborg Randomized Population-Based Prostate Cancer Screening Trial. Issue 2 (15th August 2022)

• Record Type: Journal Article
• Authors: Frånlund, Maria; Månsson, Marianne; Godtman, Rebecka Arnsrud; Aus, Gunnar; Holmberg, Erik; Kollberg, Karin Stinesen; Lodding, Pär; Pihl, Carl-Gustaf; Stranne, Johan; Lilja, Hans; Hugosson, Jonas
• Is Part Of: Journal of urology. Volume 208:Issue 2(2022)
• Page Start: 292
• Page End: 300
• Publication Date: 2022-08-15
• Subjects: prostatic neoplasms -- prostate-specific antigen -- mortality -- epidemiology -- mass screening; Genitourinary organs -- Periodicals; Urology -- Periodicals; Urology -- Periodicals; Urologie -- Périodiques; Urologie; 616.6
• DOI: 10.1097/JU.0000000000002696
• Languages: English
• ISSNs: 0022-5347

Abstract

Abstract : Purpose: Our goal was to analyze results from 22 years of followup in the Göteborg randomized prostate cancer (PC) screening trial. Materials and Methods: In December 1994, 20, 000 men born 1930–1944 were randomly extracted from the Swedish population register and were randomized (1:1) into either a screening group (SG) or to a control group (CG). Men in the SG were repeatedly invited for biennial prostate specific antigen testing up to an average age of 69 years. Main endpoints were PC incidence and mortality (intention-to-screen principle). Results: After 22 years, 1, 528 men in the SG and 1, 124 men in the CG had been diagnosed with PC. In total, 112 PC deaths occurred in the SG and 158 in the CG. Compared with the CG, the SG showed a PC incidence rate ratio (RR) of 1.42 (95% CI, 1.31–1.53) and a PC mortality RR of 0.71 (95% CI, 0.55–0.91). The 22-year cumulative PC mortality rate was 1.55% (95% CI, 1.29–1.86) in the SG and 2.13% (95% CI, 1.83–2.49) in the CG. Correction for nonattendance (Cuzick method) yielded a RR of PC mortality of 0.59 (95% CI, 0.43–0.80). Number needed to invite and number needed to diagnose was estimated to 221 and 9, respectively. PC death risk was increased in the following groups: nontesting men, men entering the program after age 60 and men with >10 years of followup after screening termination. Conclusions: Prostate specific antigen-based screening substantially decreases PC mortality. However, not attending, starting after age 60 and stopping at age 70 seem to be major pitfalls regarding PC death risk.